nodes	percent_of_prediction	percent_of_DWPC	metapath
Trabectedin—Alkylating Activity—Dacarbazine—muscle cancer	0.831	1	CiPCiCtD
Trabectedin—CYP2E1—Dacarbazine—muscle cancer	0.0389	0.371	CbGbCtD
Trabectedin—PTGS1—Etoposide—muscle cancer	0.0247	0.235	CbGbCtD
Trabectedin—CYP2E1—Etoposide—muscle cancer	0.0191	0.182	CbGbCtD
Trabectedin—CYP3A4—Vincristine—muscle cancer	0.0063	0.0601	CbGbCtD
Trabectedin—CYP2D6—Doxorubicin—muscle cancer	0.00619	0.059	CbGbCtD
Trabectedin—CYP3A4—Etoposide—muscle cancer	0.00577	0.0551	CbGbCtD
Trabectedin—CYP3A4—Doxorubicin—muscle cancer	0.00394	0.0375	CbGbCtD
Trabectedin—Mucosal inflammation—Methotrexate—muscle cancer	0.000397	0.00675	CcSEcCtD
Trabectedin—Skin hyperpigmentation—Methotrexate—muscle cancer	0.000369	0.00629	CcSEcCtD
Trabectedin—Hepatic failure—Vincristine—muscle cancer	0.000365	0.00623	CcSEcCtD
Trabectedin—Febrile neutropenia—Methotrexate—muscle cancer	0.000365	0.00622	CcSEcCtD
Trabectedin—Mucosal inflammation—Doxorubicin—muscle cancer	0.000343	0.00585	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.000331	0.00564	CcSEcCtD
Trabectedin—Skin hyperpigmentation—Doxorubicin—muscle cancer	0.00032	0.00544	CcSEcCtD
Trabectedin—Sepsis—Etoposide—muscle cancer	0.000318	0.00542	CcSEcCtD
Trabectedin—Febrile neutropenia—Doxorubicin—muscle cancer	0.000316	0.00538	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Etoposide—muscle cancer	0.000306	0.00521	CcSEcCtD
Trabectedin—Dehydration—Vincristine—muscle cancer	0.000305	0.0052	CcSEcCtD
Trabectedin—Pancytopenia—Dactinomycin—muscle cancer	0.000302	0.00514	CcSEcCtD
Trabectedin—Neutropenia—Dactinomycin—muscle cancer	0.000297	0.00506	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000296	0.00504	CcSEcCtD
Trabectedin—Hepatotoxicity—Methotrexate—muscle cancer	0.000284	0.00484	CcSEcCtD
Trabectedin—Necrosis—Methotrexate—muscle cancer	0.00028	0.00476	CcSEcCtD
Trabectedin—SRC—Signalling to ERKs—KIDINS220—muscle cancer	0.000277	0.0533	CbGpPWpGaD
Trabectedin—Stomatitis—Dactinomycin—muscle cancer	0.000276	0.0047	CcSEcCtD
Trabectedin—Pancytopenia—Vincristine—muscle cancer	0.00027	0.00459	CcSEcCtD
Trabectedin—Hepatomegaly—Doxorubicin—muscle cancer	0.000269	0.00457	CcSEcCtD
Trabectedin—Neutropenia—Vincristine—muscle cancer	0.000265	0.00452	CcSEcCtD
Trabectedin—Agranulocytosis—Dactinomycin—muscle cancer	0.000264	0.0045	CcSEcCtD
Trabectedin—Weight decreased—Vincristine—muscle cancer	0.000257	0.00437	CcSEcCtD
Trabectedin—Extravasation—Methotrexate—muscle cancer	0.000252	0.00429	CcSEcCtD
Trabectedin—Stomatitis—Vincristine—muscle cancer	0.000247	0.0042	CcSEcCtD
Trabectedin—Necrosis—Doxorubicin—muscle cancer	0.000242	0.00413	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.000241	0.00411	CcSEcCtD
Trabectedin—Flushing—Dactinomycin—muscle cancer	0.000236	0.00402	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000235	0.004	CcSEcCtD
Trabectedin—Liver injury—Doxorubicin—muscle cancer	0.000226	0.00385	CcSEcCtD
Trabectedin—Alopecia—Dactinomycin—muscle cancer	0.000225	0.00383	CcSEcCtD
Trabectedin—Connective tissue disorder—Vincristine—muscle cancer	0.000223	0.0038	CcSEcCtD
Trabectedin—Pulmonary embolism—Methotrexate—muscle cancer	0.00022	0.00374	CcSEcCtD
Trabectedin—Pancytopenia—Etoposide—muscle cancer	0.000218	0.00372	CcSEcCtD
Trabectedin—Extravasation—Doxorubicin—muscle cancer	0.000218	0.00371	CcSEcCtD
Trabectedin—Neutropenia—Etoposide—muscle cancer	0.000215	0.00366	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.000209	0.00356	CcSEcCtD
Trabectedin—Angiopathy—Vincristine—muscle cancer	0.000206	0.00351	CcSEcCtD
Trabectedin—Infestation NOS—Etoposide—muscle cancer	0.000205	0.00349	CcSEcCtD
Trabectedin—Infestation—Etoposide—muscle cancer	0.000205	0.00349	CcSEcCtD
Trabectedin—Mediastinal disorder—Vincristine—muscle cancer	0.000205	0.00349	CcSEcCtD
Trabectedin—Anaemia—Dactinomycin—muscle cancer	0.000205	0.00349	CcSEcCtD
Trabectedin—Alopecia—Vincristine—muscle cancer	0.000201	0.00342	CcSEcCtD
Trabectedin—Stomatitis—Etoposide—muscle cancer	0.0002	0.0034	CcSEcCtD
Trabectedin—Jaundice—Etoposide—muscle cancer	0.0002	0.0034	CcSEcCtD
Trabectedin—Mental disorder—Vincristine—muscle cancer	0.000199	0.00339	CcSEcCtD
Trabectedin—Leukopenia—Dactinomycin—muscle cancer	0.000198	0.00338	CcSEcCtD
Trabectedin—Pulmonary oedema—Methotrexate—muscle cancer	0.000195	0.00333	CcSEcCtD
Trabectedin—Hepatobiliary disease—Etoposide—muscle cancer	0.000194	0.0033	CcSEcCtD
Trabectedin—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000192	0.00328	CcSEcCtD
Trabectedin—Agranulocytosis—Etoposide—muscle cancer	0.000191	0.00326	CcSEcCtD
Trabectedin—Back pain—Vincristine—muscle cancer	0.000191	0.00326	CcSEcCtD
Trabectedin—Sepsis—Methotrexate—muscle cancer	0.000191	0.00325	CcSEcCtD
Trabectedin—Pulmonary embolism—Doxorubicin—muscle cancer	0.00019	0.00324	CcSEcCtD
Trabectedin—Injection site reaction—Doxorubicin—muscle cancer	0.000189	0.00322	CcSEcCtD
Trabectedin—Myalgia—Dactinomycin—muscle cancer	0.000188	0.00321	CcSEcCtD
Trabectedin—Anaemia—Vincristine—muscle cancer	0.000183	0.00311	CcSEcCtD
Trabectedin—Oedema—Dactinomycin—muscle cancer	0.000181	0.00308	CcSEcCtD
Trabectedin—Infection—Dactinomycin—muscle cancer	0.000179	0.00306	CcSEcCtD
Trabectedin—Hepatic failure—Methotrexate—muscle cancer	0.000177	0.00302	CcSEcCtD
Trabectedin—Leukopenia—Vincristine—muscle cancer	0.000177	0.00302	CcSEcCtD
Trabectedin—Thrombocytopenia—Dactinomycin—muscle cancer	0.000177	0.00301	CcSEcCtD
Trabectedin—Anorexia—Dactinomycin—muscle cancer	0.000172	0.00293	CcSEcCtD
Trabectedin—Flushing—Etoposide—muscle cancer	0.000171	0.00291	CcSEcCtD
Trabectedin—Pulmonary oedema—Doxorubicin—muscle cancer	0.000169	0.00288	CcSEcCtD
Trabectedin—Myalgia—Vincristine—muscle cancer	0.000168	0.00287	CcSEcCtD
Trabectedin—Angiopathy—Etoposide—muscle cancer	0.000167	0.00284	CcSEcCtD
Trabectedin—Mediastinal disorder—Etoposide—muscle cancer	0.000166	0.00283	CcSEcCtD
Trabectedin—Sepsis—Doxorubicin—muscle cancer	0.000165	0.00281	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000165	0.0028	CcSEcCtD
Trabectedin—Alopecia—Etoposide—muscle cancer	0.000163	0.00277	CcSEcCtD
Trabectedin—Oedema—Vincristine—muscle cancer	0.000161	0.00275	CcSEcCtD
Trabectedin—Infection—Vincristine—muscle cancer	0.00016	0.00273	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	0.000159	0.0027	CcSEcCtD
Trabectedin—Nervous system disorder—Vincristine—muscle cancer	0.000158	0.0027	CcSEcCtD
Trabectedin—Thrombocytopenia—Vincristine—muscle cancer	0.000158	0.00269	CcSEcCtD
Trabectedin—Decreased appetite—Dactinomycin—muscle cancer	0.000157	0.00268	CcSEcCtD
Trabectedin—Dysgeusia—Etoposide—muscle cancer	0.000157	0.00267	CcSEcCtD
Trabectedin—Fatigue—Dactinomycin—muscle cancer	0.000156	0.00265	CcSEcCtD
Trabectedin—Back pain—Etoposide—muscle cancer	0.000155	0.00264	CcSEcCtD
Trabectedin—Anorexia—Vincristine—muscle cancer	0.000154	0.00262	CcSEcCtD
Trabectedin—Hepatic failure—Doxorubicin—muscle cancer	0.000154	0.00262	CcSEcCtD
Trabectedin—Hypotension—Vincristine—muscle cancer	0.000151	0.00257	CcSEcCtD
Trabectedin—Anaemia—Etoposide—muscle cancer	0.000148	0.00252	CcSEcCtD
Trabectedin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000148	0.00252	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000147	0.00251	CcSEcCtD
Trabectedin—Insomnia—Vincristine—muscle cancer	0.000146	0.00249	CcSEcCtD
Trabectedin—Paraesthesia—Vincristine—muscle cancer	0.000145	0.00247	CcSEcCtD
Trabectedin—Leukopenia—Etoposide—muscle cancer	0.000143	0.00244	CcSEcCtD
Trabectedin—Abdominal pain—Dactinomycin—muscle cancer	0.000143	0.00243	CcSEcCtD
Trabectedin—Body temperature increased—Dactinomycin—muscle cancer	0.000143	0.00243	CcSEcCtD
Trabectedin—Loss of consciousness—Etoposide—muscle cancer	0.000141	0.0024	CcSEcCtD
Trabectedin—Decreased appetite—Vincristine—muscle cancer	0.00014	0.00239	CcSEcCtD
Trabectedin—Cough—Etoposide—muscle cancer	0.00014	0.00238	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Vincristine—muscle cancer	0.000139	0.00237	CcSEcCtD
Trabectedin—Fatigue—Vincristine—muscle cancer	0.000139	0.00237	CcSEcCtD
Trabectedin—Constipation—Vincristine—muscle cancer	0.000138	0.00235	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000135	0.00231	CcSEcCtD
Trabectedin—Hypersensitivity—Dactinomycin—muscle cancer	0.000133	0.00227	CcSEcCtD
Trabectedin—Gastrointestinal pain—Vincristine—muscle cancer	0.000132	0.00225	CcSEcCtD
Trabectedin—Pancytopenia—Methotrexate—muscle cancer	0.000131	0.00223	CcSEcCtD
Trabectedin—Infection—Etoposide—muscle cancer	0.00013	0.00221	CcSEcCtD
Trabectedin—Asthenia—Dactinomycin—muscle cancer	0.00013	0.00221	CcSEcCtD
Trabectedin—Blood creatinine increased—Doxorubicin—muscle cancer	0.000129	0.0022	CcSEcCtD
Trabectedin—Neutropenia—Methotrexate—muscle cancer	0.000129	0.00219	CcSEcCtD
Trabectedin—Dehydration—Doxorubicin—muscle cancer	0.000128	0.00219	CcSEcCtD
Trabectedin—Thrombocytopenia—Etoposide—muscle cancer	0.000128	0.00218	CcSEcCtD
Trabectedin—Abdominal pain—Vincristine—muscle cancer	0.000128	0.00217	CcSEcCtD
Trabectedin—Body temperature increased—Vincristine—muscle cancer	0.000128	0.00217	CcSEcCtD
Trabectedin—Skin disorder—Etoposide—muscle cancer	0.000127	0.00216	CcSEcCtD
Trabectedin—Abdominal pain upper—Doxorubicin—muscle cancer	0.000126	0.00215	CcSEcCtD
Trabectedin—Hypokalaemia—Doxorubicin—muscle cancer	0.000126	0.00214	CcSEcCtD
Trabectedin—Anorexia—Etoposide—muscle cancer	0.000125	0.00212	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000124	0.00212	CcSEcCtD
Trabectedin—Diarrhoea—Dactinomycin—muscle cancer	0.000124	0.00211	CcSEcCtD
Trabectedin—Infestation NOS—Methotrexate—muscle cancer	0.000123	0.00209	CcSEcCtD
Trabectedin—Infestation—Methotrexate—muscle cancer	0.000123	0.00209	CcSEcCtD
Trabectedin—Hypotension—Etoposide—muscle cancer	0.000122	0.00208	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000122	0.00207	CcSEcCtD
Trabectedin—Stomatitis—Methotrexate—muscle cancer	0.00012	0.00204	CcSEcCtD
Trabectedin—Hypersensitivity—Vincristine—muscle cancer	0.000119	0.00203	CcSEcCtD
Trabectedin—SRC—Regulation of KIT signaling—KIT—muscle cancer	0.000119	0.0228	CbGpPWpGaD
Trabectedin—Paraesthesia—Etoposide—muscle cancer	0.000117	0.002	CcSEcCtD
Trabectedin—Dyspnoea—Etoposide—muscle cancer	0.000117	0.00199	CcSEcCtD
Trabectedin—Hepatobiliary disease—Methotrexate—muscle cancer	0.000116	0.00198	CcSEcCtD
Trabectedin—Asthenia—Vincristine—muscle cancer	0.000116	0.00197	CcSEcCtD
Trabectedin—Vomiting—Dactinomycin—muscle cancer	0.000115	0.00196	CcSEcCtD
Trabectedin—Agranulocytosis—Methotrexate—muscle cancer	0.000115	0.00195	CcSEcCtD
Trabectedin—Rash—Dactinomycin—muscle cancer	0.000114	0.00194	CcSEcCtD
Trabectedin—Decreased appetite—Etoposide—muscle cancer	0.000114	0.00194	CcSEcCtD
Trabectedin—Pancytopenia—Doxorubicin—muscle cancer	0.000113	0.00193	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Etoposide—muscle cancer	0.000113	0.00192	CcSEcCtD
Trabectedin—Fatigue—Etoposide—muscle cancer	0.000113	0.00192	CcSEcCtD
Trabectedin—SRC—Class I PI3K signaling events mediated by Akt—FOXO4—muscle cancer	0.000113	0.0217	CbGpPWpGaD
Trabectedin—Constipation—Etoposide—muscle cancer	0.000112	0.0019	CcSEcCtD
Trabectedin—Neutropenia—Doxorubicin—muscle cancer	0.000112	0.0019	CcSEcCtD
Trabectedin—Haemoglobin—Methotrexate—muscle cancer	0.000111	0.00189	CcSEcCtD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—ANGPT2—muscle cancer	0.000111	0.0213	CbGpPWpGaD
Trabectedin—Diarrhoea—Vincristine—muscle cancer	0.00011	0.00188	CcSEcCtD
Trabectedin—Haemorrhage—Methotrexate—muscle cancer	0.00011	0.00188	CcSEcCtD
Trabectedin—Weight decreased—Doxorubicin—muscle cancer	0.000108	0.00184	CcSEcCtD
Trabectedin—SRC—Membrane Trafficking—ASPSCR1—muscle cancer	0.000108	0.0207	CbGpPWpGaD
Trabectedin—Nausea—Dactinomycin—muscle cancer	0.000107	0.00183	CcSEcCtD
Trabectedin—SRC—BDNF signaling pathway—KIDINS220—muscle cancer	0.000107	0.0206	CbGpPWpGaD
Trabectedin—Gastrointestinal pain—Etoposide—muscle cancer	0.000107	0.00182	CcSEcCtD
Trabectedin—Dizziness—Vincristine—muscle cancer	0.000107	0.00182	CcSEcCtD
Trabectedin—Infestation NOS—Doxorubicin—muscle cancer	0.000106	0.00181	CcSEcCtD
Trabectedin—Infestation—Doxorubicin—muscle cancer	0.000106	0.00181	CcSEcCtD
Trabectedin—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—muscle cancer	0.000105	0.0202	CbGpPWpGaD
Trabectedin—Stomatitis—Doxorubicin—muscle cancer	0.000104	0.00177	CcSEcCtD
Trabectedin—Jaundice—Doxorubicin—muscle cancer	0.000104	0.00177	CcSEcCtD
Trabectedin—Abdominal pain—Etoposide—muscle cancer	0.000103	0.00176	CcSEcCtD
Trabectedin—Body temperature increased—Etoposide—muscle cancer	0.000103	0.00176	CcSEcCtD
Trabectedin—Vomiting—Vincristine—muscle cancer	0.000103	0.00175	CcSEcCtD
Trabectedin—SRC—FSH signaling pathway—FOXO1—muscle cancer	0.000102	0.0197	CbGpPWpGaD
Trabectedin—Rash—Vincristine—muscle cancer	0.000102	0.00173	CcSEcCtD
Trabectedin—Dermatitis—Vincristine—muscle cancer	0.000102	0.00173	CcSEcCtD
Trabectedin—Headache—Vincristine—muscle cancer	0.000101	0.00172	CcSEcCtD
Trabectedin—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000101	0.00171	CcSEcCtD
Trabectedin—Angiopathy—Methotrexate—muscle cancer	0.0001	0.0017	CcSEcCtD
Trabectedin—Mediastinal disorder—Methotrexate—muscle cancer	9.94e-05	0.00169	CcSEcCtD
Trabectedin—Agranulocytosis—Doxorubicin—muscle cancer	9.92e-05	0.00169	CcSEcCtD
Trabectedin—Alopecia—Methotrexate—muscle cancer	9.74e-05	0.00166	CcSEcCtD
Trabectedin—Mental disorder—Methotrexate—muscle cancer	9.66e-05	0.00165	CcSEcCtD
Trabectedin—Hypersensitivity—Etoposide—muscle cancer	9.63e-05	0.00164	CcSEcCtD
Trabectedin—Malnutrition—Methotrexate—muscle cancer	9.6e-05	0.00163	CcSEcCtD
Trabectedin—Haemoglobin—Doxorubicin—muscle cancer	9.59e-05	0.00163	CcSEcCtD
Trabectedin—Nausea—Vincristine—muscle cancer	9.59e-05	0.00163	CcSEcCtD
Trabectedin—Haemorrhage—Doxorubicin—muscle cancer	9.55e-05	0.00163	CcSEcCtD
Trabectedin—Oedema peripheral—Doxorubicin—muscle cancer	9.4e-05	0.0016	CcSEcCtD
Trabectedin—Dysgeusia—Methotrexate—muscle cancer	9.4e-05	0.0016	CcSEcCtD
Trabectedin—Asthenia—Etoposide—muscle cancer	9.38e-05	0.0016	CcSEcCtD
Trabectedin—Connective tissue disorder—Doxorubicin—muscle cancer	9.38e-05	0.0016	CcSEcCtD
Trabectedin—Back pain—Methotrexate—muscle cancer	9.28e-05	0.00158	CcSEcCtD
Trabectedin—Diarrhoea—Etoposide—muscle cancer	8.95e-05	0.00152	CcSEcCtD
Trabectedin—Anaemia—Methotrexate—muscle cancer	8.87e-05	0.00151	CcSEcCtD
Trabectedin—Flushing—Doxorubicin—muscle cancer	8.86e-05	0.00151	CcSEcCtD
Trabectedin—Angiopathy—Doxorubicin—muscle cancer	8.66e-05	0.00148	CcSEcCtD
Trabectedin—Dizziness—Etoposide—muscle cancer	8.65e-05	0.00147	CcSEcCtD
Trabectedin—Mediastinal disorder—Doxorubicin—muscle cancer	8.6e-05	0.00147	CcSEcCtD
Trabectedin—Leukopenia—Methotrexate—muscle cancer	8.59e-05	0.00146	CcSEcCtD
Trabectedin—Alopecia—Doxorubicin—muscle cancer	8.44e-05	0.00144	CcSEcCtD
Trabectedin—Cough—Methotrexate—muscle cancer	8.37e-05	0.00143	CcSEcCtD
Trabectedin—Mental disorder—Doxorubicin—muscle cancer	8.36e-05	0.00142	CcSEcCtD
Trabectedin—SRC—Class I PI3K signaling events mediated by Akt—FOXO1—muscle cancer	8.32e-05	0.016	CbGpPWpGaD
Trabectedin—Vomiting—Etoposide—muscle cancer	8.31e-05	0.00142	CcSEcCtD
Trabectedin—Malnutrition—Doxorubicin—muscle cancer	8.31e-05	0.00142	CcSEcCtD
Trabectedin—PTGS1—Overview of nanoparticle effects—PTGS2—muscle cancer	8.25e-05	0.0159	CbGpPWpGaD
Trabectedin—Rash—Etoposide—muscle cancer	8.24e-05	0.0014	CcSEcCtD
Trabectedin—Dermatitis—Etoposide—muscle cancer	8.24e-05	0.0014	CcSEcCtD
Trabectedin—Headache—Etoposide—muscle cancer	8.19e-05	0.0014	CcSEcCtD
Trabectedin—Myalgia—Methotrexate—muscle cancer	8.17e-05	0.00139	CcSEcCtD
Trabectedin—Arthralgia—Methotrexate—muscle cancer	8.17e-05	0.00139	CcSEcCtD
Trabectedin—Dysgeusia—Doxorubicin—muscle cancer	8.14e-05	0.00139	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.11e-05	0.00138	CcSEcCtD
Trabectedin—SRC—Cell surface interactions at the vascular wall—ANGPT2—muscle cancer	8.09e-05	0.0156	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—KIDINS220—muscle cancer	8.06e-05	0.0155	CbGpPWpGaD
Trabectedin—Back pain—Doxorubicin—muscle cancer	8.04e-05	0.00137	CcSEcCtD
Trabectedin—Infection—Methotrexate—muscle cancer	7.78e-05	0.00133	CcSEcCtD
Trabectedin—Nausea—Etoposide—muscle cancer	7.77e-05	0.00132	CcSEcCtD
Trabectedin—Nervous system disorder—Methotrexate—muscle cancer	7.68e-05	0.00131	CcSEcCtD
Trabectedin—Anaemia—Doxorubicin—muscle cancer	7.68e-05	0.00131	CcSEcCtD
Trabectedin—Thrombocytopenia—Methotrexate—muscle cancer	7.67e-05	0.00131	CcSEcCtD
Trabectedin—Skin disorder—Methotrexate—muscle cancer	7.61e-05	0.0013	CcSEcCtD
Trabectedin—Anorexia—Methotrexate—muscle cancer	7.47e-05	0.00127	CcSEcCtD
Trabectedin—Syncope—Doxorubicin—muscle cancer	7.45e-05	0.00127	CcSEcCtD
Trabectedin—Leukopenia—Doxorubicin—muscle cancer	7.44e-05	0.00127	CcSEcCtD
Trabectedin—Hypotension—Methotrexate—muscle cancer	7.32e-05	0.00125	CcSEcCtD
Trabectedin—Loss of consciousness—Doxorubicin—muscle cancer	7.3e-05	0.00124	CcSEcCtD
Trabectedin—Cough—Doxorubicin—muscle cancer	7.25e-05	0.00124	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Methotrexate—muscle cancer	7.14e-05	0.00122	CcSEcCtD
Trabectedin—Insomnia—Methotrexate—muscle cancer	7.08e-05	0.00121	CcSEcCtD
Trabectedin—Arthralgia—Doxorubicin—muscle cancer	7.07e-05	0.00121	CcSEcCtD
Trabectedin—Myalgia—Doxorubicin—muscle cancer	7.07e-05	0.00121	CcSEcCtD
Trabectedin—Paraesthesia—Methotrexate—muscle cancer	7.03e-05	0.0012	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.03e-05	0.0012	CcSEcCtD
Trabectedin—SRC—Posttranslational regulation of adherens junction stability and dissassembly—IGF2—muscle cancer	7.02e-05	0.0135	CbGpPWpGaD
Trabectedin—Dyspnoea—Methotrexate—muscle cancer	6.98e-05	0.00119	CcSEcCtD
Trabectedin—Dyspepsia—Methotrexate—muscle cancer	6.89e-05	0.00117	CcSEcCtD
Trabectedin—PTGS1—Eicosanoid Synthesis—PTGS2—muscle cancer	6.84e-05	0.0132	CbGpPWpGaD
Trabectedin—Decreased appetite—Methotrexate—muscle cancer	6.81e-05	0.00116	CcSEcCtD
Trabectedin—Oedema—Doxorubicin—muscle cancer	6.78e-05	0.00116	CcSEcCtD
Trabectedin—SRC—AGE/RAGE pathway—FOXO4—muscle cancer	6.78e-05	0.013	CbGpPWpGaD
Trabectedin—Gastrointestinal disorder—Methotrexate—muscle cancer	6.76e-05	0.00115	CcSEcCtD
Trabectedin—Fatigue—Methotrexate—muscle cancer	6.75e-05	0.00115	CcSEcCtD
Trabectedin—Infection—Doxorubicin—muscle cancer	6.74e-05	0.00115	CcSEcCtD
Trabectedin—Shock—Doxorubicin—muscle cancer	6.67e-05	0.00114	CcSEcCtD
Trabectedin—Nervous system disorder—Doxorubicin—muscle cancer	6.65e-05	0.00113	CcSEcCtD
Trabectedin—Thrombocytopenia—Doxorubicin—muscle cancer	6.64e-05	0.00113	CcSEcCtD
Trabectedin—Skin disorder—Doxorubicin—muscle cancer	6.59e-05	0.00112	CcSEcCtD
Trabectedin—Anorexia—Doxorubicin—muscle cancer	6.46e-05	0.0011	CcSEcCtD
Trabectedin—Gastrointestinal pain—Methotrexate—muscle cancer	6.4e-05	0.00109	CcSEcCtD
Trabectedin—Hypotension—Doxorubicin—muscle cancer	6.34e-05	0.00108	CcSEcCtD
Trabectedin—SRC—Signaling by NGF—KIDINS220—muscle cancer	6.2e-05	0.0119	CbGpPWpGaD
Trabectedin—Abdominal pain—Methotrexate—muscle cancer	6.19e-05	0.00105	CcSEcCtD
Trabectedin—Body temperature increased—Methotrexate—muscle cancer	6.19e-05	0.00105	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6.18e-05	0.00105	CcSEcCtD
Trabectedin—Insomnia—Doxorubicin—muscle cancer	6.13e-05	0.00104	CcSEcCtD
Trabectedin—Paraesthesia—Doxorubicin—muscle cancer	6.09e-05	0.00104	CcSEcCtD
Trabectedin—Dyspnoea—Doxorubicin—muscle cancer	6.05e-05	0.00103	CcSEcCtD
Trabectedin—Dyspepsia—Doxorubicin—muscle cancer	5.97e-05	0.00102	CcSEcCtD
Trabectedin—SRC—Regulation of Androgen receptor activity—FOXO1—muscle cancer	5.97e-05	0.0115	CbGpPWpGaD
Trabectedin—Decreased appetite—Doxorubicin—muscle cancer	5.9e-05	0.001	CcSEcCtD
Trabectedin—SRC—ErbB Signaling Pathway—FOXO1—muscle cancer	5.88e-05	0.0113	CbGpPWpGaD
Trabectedin—CYP2C19—Melatonin metabolism and effects—FOXO1—muscle cancer	5.86e-05	0.0113	CbGpPWpGaD
Trabectedin—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.86e-05	0.000997	CcSEcCtD
Trabectedin—Fatigue—Doxorubicin—muscle cancer	5.85e-05	0.000996	CcSEcCtD
Trabectedin—Constipation—Doxorubicin—muscle cancer	5.8e-05	0.000988	CcSEcCtD
Trabectedin—Hypersensitivity—Methotrexate—muscle cancer	5.77e-05	0.000983	CcSEcCtD
Trabectedin—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	5.72e-05	0.011	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—FOXO4—muscle cancer	5.7e-05	0.011	CbGpPWpGaD
Trabectedin—Asthenia—Methotrexate—muscle cancer	5.62e-05	0.000957	CcSEcCtD
Trabectedin—Gastrointestinal pain—Doxorubicin—muscle cancer	5.55e-05	0.000945	CcSEcCtD
Trabectedin—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	5.42e-05	0.0104	CbGpPWpGaD
Trabectedin—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	5.39e-05	0.0104	CbGpPWpGaD
Trabectedin—Abdominal pain—Doxorubicin—muscle cancer	5.36e-05	0.000913	CcSEcCtD
Trabectedin—Body temperature increased—Doxorubicin—muscle cancer	5.36e-05	0.000913	CcSEcCtD
Trabectedin—Diarrhoea—Methotrexate—muscle cancer	5.36e-05	0.000913	CcSEcCtD
Trabectedin—SRC—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	5.21e-05	0.01	CbGpPWpGaD
Trabectedin—Dizziness—Methotrexate—muscle cancer	5.18e-05	0.000882	CcSEcCtD
Trabectedin—SRC—Angiogenesis—VEGFA—muscle cancer	5.13e-05	0.00986	CbGpPWpGaD
Trabectedin—SRC—AGE/RAGE pathway—FOXO1—muscle cancer	5.01e-05	0.00963	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MYF5—muscle cancer	5.01e-05	0.00963	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MYF6—muscle cancer	5.01e-05	0.00963	CbGpPWpGaD
Trabectedin—Hypersensitivity—Doxorubicin—muscle cancer	5e-05	0.000851	CcSEcCtD
Trabectedin—Vomiting—Methotrexate—muscle cancer	4.98e-05	0.000848	CcSEcCtD
Trabectedin—SRC—Alpha9 beta1 integrin signaling events—VEGFA—muscle cancer	4.96e-05	0.00954	CbGpPWpGaD
Trabectedin—SRC—S1P3 pathway—VEGFA—muscle cancer	4.96e-05	0.00954	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—FOXO1—muscle cancer	4.95e-05	0.00951	CbGpPWpGaD
Trabectedin—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	4.94e-05	0.0095	CbGpPWpGaD
Trabectedin—Rash—Methotrexate—muscle cancer	4.94e-05	0.000841	CcSEcCtD
Trabectedin—Dermatitis—Methotrexate—muscle cancer	4.93e-05	0.00084	CcSEcCtD
Trabectedin—Headache—Methotrexate—muscle cancer	4.91e-05	0.000836	CcSEcCtD
Trabectedin—Asthenia—Doxorubicin—muscle cancer	4.87e-05	0.000829	CcSEcCtD
Trabectedin—SRC—Glypican 1 network—VEGFA—muscle cancer	4.81e-05	0.00925	CbGpPWpGaD
Trabectedin—SRC—GAB1 signalosome—FOXO4—muscle cancer	4.79e-05	0.0092	CbGpPWpGaD
Trabectedin—Nausea—Methotrexate—muscle cancer	4.65e-05	0.000793	CcSEcCtD
Trabectedin—Diarrhoea—Doxorubicin—muscle cancer	4.64e-05	0.00079	CcSEcCtD
Trabectedin—SRC—Leptin signaling pathway—FOXO1—muscle cancer	4.52e-05	0.00869	CbGpPWpGaD
Trabectedin—Dizziness—Doxorubicin—muscle cancer	4.48e-05	0.000764	CcSEcCtD
Trabectedin—Vomiting—Doxorubicin—muscle cancer	4.31e-05	0.000735	CcSEcCtD
Trabectedin—Rash—Doxorubicin—muscle cancer	4.28e-05	0.000728	CcSEcCtD
Trabectedin—Dermatitis—Doxorubicin—muscle cancer	4.27e-05	0.000728	CcSEcCtD
Trabectedin—Headache—Doxorubicin—muscle cancer	4.25e-05	0.000724	CcSEcCtD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—FOXO1—muscle cancer	4.21e-05	0.00809	CbGpPWpGaD
Trabectedin—SRC—Kit receptor signaling pathway—KIT—muscle cancer	4.17e-05	0.00803	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—FOXO1—muscle cancer	4.13e-05	0.00794	CbGpPWpGaD
Trabectedin—Nausea—Doxorubicin—muscle cancer	4.03e-05	0.000686	CcSEcCtD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	3.96e-05	0.00762	CbGpPWpGaD
Trabectedin—SRC—Androgen receptor signaling pathway—FOXO1—muscle cancer	3.94e-05	0.00758	CbGpPWpGaD
Trabectedin—SRC—VEGFR2 mediated cell proliferation—VEGFA—muscle cancer	3.88e-05	0.00746	CbGpPWpGaD
Trabectedin—SRC—EPHA-mediated growth cone collapse—VEGFA—muscle cancer	3.88e-05	0.00746	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	3.87e-05	0.00744	CbGpPWpGaD
Trabectedin—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	3.8e-05	0.00731	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—FOXO4—muscle cancer	3.69e-05	0.0071	CbGpPWpGaD
Trabectedin—SRC—Regulation of Androgen receptor activity—MDM2—muscle cancer	3.58e-05	0.00689	CbGpPWpGaD
Trabectedin—SRC—BDNF signaling pathway—CNR1—muscle cancer	3.57e-05	0.00686	CbGpPWpGaD
Trabectedin—SRC—GAB1 signalosome—FOXO1—muscle cancer	3.53e-05	0.0068	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—MDM2—muscle cancer	3.53e-05	0.00679	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by TCPTP—VEGFA—muscle cancer	3.41e-05	0.00655	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—FOXO4—muscle cancer	3.32e-05	0.00639	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—FOXO4—muscle cancer	3.31e-05	0.00636	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	3.31e-05	0.00636	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—FOXO4—muscle cancer	3.29e-05	0.00633	CbGpPWpGaD
Trabectedin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	3.26e-05	0.00626	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MYOG—muscle cancer	3.23e-05	0.0062	CbGpPWpGaD
Trabectedin—CYP2E1—Tryptophan metabolism—MDM2—muscle cancer	3.15e-05	0.00606	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—FOXO4—muscle cancer	3.08e-05	0.00592	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—FOXO4—muscle cancer	3.05e-05	0.00587	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.05e-05	0.00586	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—FOXO4—muscle cancer	3.02e-05	0.00582	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—FOXO4—muscle cancer	3.01e-05	0.00579	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.9e-05	0.00557	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—FOXO1—muscle cancer	2.73e-05	0.00525	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	2.73e-05	0.00525	CbGpPWpGaD
Trabectedin—SRC—GAB1 signalosome—KIT—muscle cancer	2.69e-05	0.00518	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	2.6e-05	0.00501	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	2.53e-05	0.00486	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—FOXO1—muscle cancer	2.45e-05	0.00472	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—FOXO1—muscle cancer	2.44e-05	0.0047	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	2.44e-05	0.0047	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—FOXO1—muscle cancer	2.43e-05	0.00467	CbGpPWpGaD
Trabectedin—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	2.42e-05	0.00465	CbGpPWpGaD
Trabectedin—SRC—Integrins in angiogenesis—VEGFA—muscle cancer	2.37e-05	0.00455	CbGpPWpGaD
Trabectedin—SRC—Androgen receptor signaling pathway—MDM2—muscle cancer	2.37e-05	0.00455	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	2.31e-05	0.00444	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—FOXO1—muscle cancer	2.27e-05	0.00437	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—FOXO1—muscle cancer	2.25e-05	0.00433	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—FOXO1—muscle cancer	2.23e-05	0.0043	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—muscle cancer	2.23e-05	0.00428	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—FOXO1—muscle cancer	2.22e-05	0.00428	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—ANGPT2—muscle cancer	2.19e-05	0.00422	CbGpPWpGaD
Trabectedin—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	2.19e-05	0.00422	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	2.14e-05	0.00411	CbGpPWpGaD
Trabectedin—SRC—GAB1 signalosome—MDM2—muscle cancer	2.12e-05	0.00408	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—FOXO4—muscle cancer	2.1e-05	0.00403	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—KIT—muscle cancer	2.08e-05	0.004	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—MDM2—muscle cancer	2.07e-05	0.00399	CbGpPWpGaD
Trabectedin—SRC—Platelet activation, signaling and aggregation—IGF2—muscle cancer	2.07e-05	0.00398	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—TP53—muscle cancer	2.02e-05	0.00389	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	2.01e-05	0.00387	CbGpPWpGaD
Trabectedin—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	2e-05	0.00384	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MYOD1—muscle cancer	1.99e-05	0.00383	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—KIT—muscle cancer	1.87e-05	0.0036	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—KIT—muscle cancer	1.86e-05	0.00358	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—KIT—muscle cancer	1.85e-05	0.00356	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MED12—muscle cancer	1.82e-05	0.00351	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—TP53—muscle cancer	1.75e-05	0.00336	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—KIT—muscle cancer	1.73e-05	0.00333	CbGpPWpGaD
Trabectedin—SRC—EPH-Ephrin signaling—VEGFA—muscle cancer	1.72e-05	0.00331	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—KIT—muscle cancer	1.72e-05	0.0033	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.71e-05	0.00329	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	1.7e-05	0.00328	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—KIT—muscle cancer	1.7e-05	0.00327	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—KIT—muscle cancer	1.69e-05	0.00326	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—CD34—muscle cancer	1.69e-05	0.00325	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—MDM2—muscle cancer	1.64e-05	0.00315	CbGpPWpGaD
Trabectedin—SRC—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	1.55e-05	0.00298	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—FOXO1—muscle cancer	1.55e-05	0.00298	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	1.53e-05	0.00295	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—MDM2—muscle cancer	1.47e-05	0.00283	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—MDM2—muscle cancer	1.47e-05	0.00282	CbGpPWpGaD
Trabectedin—SRC—Signaling by VEGF—VEGFA—muscle cancer	1.46e-05	0.00281	CbGpPWpGaD
Trabectedin—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	1.46e-05	0.00281	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—MDM2—muscle cancer	1.46e-05	0.0028	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—TP53—muscle cancer	1.45e-05	0.00279	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—MDM2—muscle cancer	1.36e-05	0.00262	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—MDM2—muscle cancer	1.35e-05	0.0026	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—FH—muscle cancer	1.35e-05	0.00259	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—MDM2—muscle cancer	1.34e-05	0.00258	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—MDM2—muscle cancer	1.33e-05	0.00257	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—KIDINS220—muscle cancer	1.33e-05	0.00256	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.28e-05	0.00247	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.24e-05	0.00238	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	1.21e-05	0.00232	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—FOXO4—muscle cancer	1.2e-05	0.0023	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—TP53—muscle cancer	1.19e-05	0.00229	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—KIT—muscle cancer	1.18e-05	0.00227	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—FOXO4—muscle cancer	1.15e-05	0.00221	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—IGF2—muscle cancer	1.07e-05	0.00205	CbGpPWpGaD
Trabectedin—SRC—Immune System—CD34—muscle cancer	1.03e-05	0.00197	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—FH—muscle cancer	1.01e-05	0.00194	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—FOXO1—muscle cancer	1e-05	0.00192	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—TP53—muscle cancer	9.9e-06	0.0019	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.87e-06	0.0019	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—VEGFA—muscle cancer	9.79e-06	0.00188	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	9.75e-06	0.00188	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—MDM2—muscle cancer	9.3e-06	0.00179	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9e-06	0.00173	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—FOXO1—muscle cancer	8.84e-06	0.0017	CbGpPWpGaD
Trabectedin—SRC—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	8.68e-06	0.00167	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—FOXO1—muscle cancer	8.49e-06	0.00163	CbGpPWpGaD
Trabectedin—SRC—Disease—ENO2—muscle cancer	7.89e-06	0.00152	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—FH—muscle cancer	7.78e-06	0.0015	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—MED12—muscle cancer	7.62e-06	0.00147	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	7.37e-06	0.00142	CbGpPWpGaD
Trabectedin—SRC—Disease—HMGA1—muscle cancer	7.17e-06	0.00138	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—FH—muscle cancer	7.15e-06	0.00138	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—FH—muscle cancer	7.09e-06	0.00136	CbGpPWpGaD
Trabectedin—SRC—Immune System—FOXO4—muscle cancer	6.97e-06	0.00134	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—ENO2—muscle cancer	6.95e-06	0.00134	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—KIT—muscle cancer	6.73e-06	0.00129	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—KIT—muscle cancer	6.47e-06	0.00124	CbGpPWpGaD
Trabectedin—SRC—Disease—FOXO4—muscle cancer	6.43e-06	0.00124	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—VEGFA—muscle cancer	6.39e-06	0.00123	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—MED12—muscle cancer	5.7e-06	0.0011	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.43e-06	0.00105	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—MDM2—muscle cancer	5.3e-06	0.00102	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PTCH1—muscle cancer	5.24e-06	0.00101	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—ENO2—muscle cancer	5.19e-06	0.000999	CbGpPWpGaD
Trabectedin—SRC—Immune System—FOXO1—muscle cancer	5.15e-06	0.00099	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—MDM2—muscle cancer	5.09e-06	0.000979	CbGpPWpGaD
Trabectedin—SRC—Disease—FOXO1—muscle cancer	4.75e-06	0.000914	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—FH—muscle cancer	4.68e-06	0.000899	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—VEGFA—muscle cancer	4.56e-06	0.000877	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—FOXO4—muscle cancer	4.51e-06	0.000867	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—VEGFA—muscle cancer	4.47e-06	0.00086	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CNR1—muscle cancer	4.42e-06	0.000851	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—MED12—muscle cancer	4.39e-06	0.000845	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—MED12—muscle cancer	4.04e-06	0.000777	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—MED12—muscle cancer	4.01e-06	0.000771	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—ENO2—muscle cancer	4.01e-06	0.000771	CbGpPWpGaD
Trabectedin—SRC—Immune System—KIT—muscle cancer	3.92e-06	0.000754	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—ENO2—muscle cancer	3.69e-06	0.000709	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—ENO2—muscle cancer	3.65e-06	0.000703	CbGpPWpGaD
Trabectedin—SRC—Disease—KIT—muscle cancer	3.62e-06	0.000696	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IGF2—muscle cancer	3.62e-06	0.000695	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—TP53—muscle cancer	3.38e-06	0.00065	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—FOXO1—muscle cancer	3.33e-06	0.00064	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.13e-06	0.000603	CbGpPWpGaD
Trabectedin—SRC—Immune System—MDM2—muscle cancer	3.09e-06	0.000594	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.86e-06	0.000549	CbGpPWpGaD
Trabectedin—SRC—Disease—MDM2—muscle cancer	2.85e-06	0.000548	CbGpPWpGaD
Trabectedin—SRC—Disease—PTGS2—muscle cancer	2.75e-06	0.000529	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—MED12—muscle cancer	2.64e-06	0.000508	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—KIT—muscle cancer	2.54e-06	0.000488	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PTGS2—muscle cancer	2.42e-06	0.000465	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—ENO2—muscle cancer	2.41e-06	0.000463	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MDM2—muscle cancer	2e-06	0.000384	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PTGS2—muscle cancer	1.81e-06	0.000348	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—VEGFA—muscle cancer	1.52e-06	0.000292	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PTGS2—muscle cancer	1.4e-06	0.000268	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PTGS2—muscle cancer	1.28e-06	0.000247	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PTGS2—muscle cancer	1.27e-06	0.000245	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TP53—muscle cancer	1.15e-06	0.00022	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PTGS2—muscle cancer	8.39e-07	0.000161	CbGpPWpGaD
